Efficacy of Albendazole to Treat Intestinal Helminths and Its Effect on Gut Microflora
NCT ID: NCT01192802
Last Updated: 2013-01-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
200 participants
INTERVENTIONAL
2010-08-31
2012-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Assessment of Drug Efficacy of Local Albendazole
NCT02420574
Monitoring the Efficacy of Anthelmintics for the Treatment of Soil Transmitted Helminths P2
NCT01379326
Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis
NCT01905423
A Study to Assess the Efficacy and Safety of Mebendazole for the Treatment of Helminth Infections in Pediatric Participants
NCT02034162
The Effectiveness of Albendazole Treatment Among Infected Toxocara Children
NCT05208333
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1 dose, Albendazole , tablet
albendazole
single 1 tablet of 400 mg of albendazole
2 doses, albendazole, tablet
1 tablet of 400 mg of albendazole per day for two consecutive days
albendazole
1 tablet of 400 mg of albendazole per day for two consecutive days
3 doses albendazole, 400mg, tablet
albendazole
1 tablet of 400 mg of albendazole per day for three consecutive days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
albendazole
1 tablet of 400 mg of albendazole per day for three consecutive days
albendazole
single 1 tablet of 400 mg of albendazole
albendazole
1 tablet of 400 mg of albendazole per day for two consecutive days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* No intestinal helminths
4 Years
14 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Albert Schweitzer Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Medical Research Unit
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medical research Unit of Lambaréné
Lambaréné, Moyen-Ogooué Province, Gabon
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Adegnika AA, Zinsou JF, Issifou S, Ateba-Ngoa U, Kassa RF, Feugap EN, Honkpehedji YJ, Dejon Agobe JC, Kenguele HM, Massinga-Loembe M, Agnandji ST, Mordmuller B, Ramharter M, Yazdanbakhsh M, Kremsner PG, Lell B. Randomized, controlled, assessor-blind clinical trial to assess the efficacy of single- versus repeated-dose albendazole to treat ascaris lumbricoides, trichuris trichiura, and hookworm infection. Antimicrob Agents Chemother. 2014 May;58(5):2535-40. doi: 10.1128/AAC.01317-13. Epub 2014 Feb 18.
Related Links
Access external resources that provide additional context or updates about the study.
Medical Research Unit of the Albert Schweitzer Hospital
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Albendazole-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.